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Abstract 
Computer search for probable T-epitopes of hepatitis A virus capsid proteins was performed using an integrated set of programs. Eight segments 
of the VPl, VP2, VP3 and VP4 proteins were chosen and synthesised. Five peptides previously examined as probable B-epitopes were used as well. 
All the peptides were tested for their ability to stimulate proliferation of lymph node T-cells primed with synthetic peptides. Almost all predicted 
T-epitopes affected the T-cell proliferation. None of the peptides had mitogenic activity. We demonstrated that regions 17-33 and 276-298 of VP1 
are possible immunodominant promiscuous ites activating lymphocytes of all mouse haplotypes. 
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1. Introduction 
Hepatitis A virus (HAV) belongs to the picornavirus 
family with a host range restricted to certain primates [l]. 
Hygienic measures alone will not suthce to control the 
occurrence of hepatitis A; rather, well-targeted vaccina- 
tion programs will be necessary to prevent epidemics. A 
number of approaches to the development of live or 
attenuated vaccines have been described [2]. However, 
the special features of HAV growing in cell cultures place 
limitations on the application of such vaccines. Attempts 
to design a subunit HAV vaccine have also been de- 
scribed [3]. Synthetic peptide vaccine may be another 
alternative, but so far there are no clear data about the 
localisation of immunogenic and antigenic determinants 
on the HAV capsid [4,5]. Results of priming the virus 
neutralising response after immunisation with HAV re- 
combinant proteins suggest hat the VP2 protein con- 
tains an epitope directly activating T helper cells; other 
epitopes must be present in VP3 and VP1 proteins [3]. 
Recent studies showed a T-cell response to recombinant 
HAV capsid proteins containing sequences from the car- 
boxy-terminal of VP1 [6]. 
The present study dealt with a search for T-epitopes 
of HAV capsid proteins. Localization of T-epitopes 
could be important for developing a synthetic vaccine. 
We have also considered that synthetic T-epitopes alone 
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are able to prime cellular immunity against the viral 
infection [7,8]. By computer sequence analyses of HAV 
capsid proteins we predicted a number of T-epitopes, 
synthesised and tested them for their ability to stimulate 
proliferation of lymph node T-cells primed with syn- 
thetic peptides. 
2. Materials and methods 
2.1. Synthetic peptides 
Peptides were synthesised by a solid-phase method on a modern&d 
Beckman 990 peptide synthesiser using PAM resin [9] and HOBt esters 
of Boc amino acids as described earlier [5J The synthesised peptides 
were cleaved from resin and deprotected by treatment with liquid HF 
containing p-cresol, and puritled by reverse-phase HPLC. The amino 
acid analysis of peptides was consistent with their expected composi- 
tions. The molecular masses of peptides were confirmed by FAB mass 
spectra. 
2.2. Mice 
BALB/c, CBA, F,(BALB/c x C,,Bl,) and F,(CBA x C&B&) strains 
were obtained from the breedine colonv at the Central Nursery of 
Laboratory Animals (Russian Academy of Medical Sciences, Kras- 
nogorsk, Russian Federation). Mice were used at 68 weeks of age and 
were of either sex. 
2.3. Lymph node T-cell proliferation assays 
Mice were immunized with 200 pg of peptide antigen in 0.20 ml 
complete Freund’s adjuvant (CFA) in two foot pads and in the base of 
the tail. Eight days later, the draining lymph nodes were removed, and 
a single-cell suspension was assayed in triplicate cultures with appropri- 
ate doses of antigen (O.l-lOO&ml) at 4 x 10’ cells per well in 96-well 
U-bottom Titertek plates in complete RPM1 1640 medium as described 
in [lO,ll]. [‘HH’hymidine incorporation into DNA during the last 16 
h of a 5&y culture was determined as a measure of proliferation. 
Stimulation indices (SI) of proliferation were calculated by the follow- 
ing formula: 
sI = X cpm [Hlthymidine incorporated with peptide 
X cpm [3H]thymidine incorporated without peptide 
An SI of 2 or more was considered positive. 
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3. Results and discussion 
The known protein Tepitopes am limited in number and 
share several common features. A high percentage of these 
regions is found within the helical segments of the intact 
protein and/or can be presented as amphipathic helices 
[12]. Therefore methods for prediction the amphipathic 
helices are the most widespread techniques for T-epitope 
searches. One such technique employs the method 
known as the ‘power spectrum’ procedure: the segment 
is considered an optimal T-epitope if the hydrophobicity 
of residues alternates with a frequency similar to the 
number of residues per turn in the a-helix [ 12,131. 
We used a standard AMPHI program [13] to predict 
sites with periodic alterations in hydrophobic and hydro- 
philic residues as probable T-epitopes. Fig. 1 presents a 
plot of the amphipathicity calculated for the VP1 capsid 
protein: the dominant peaks correspond to the most 
probable T-epitopes. Regions overlapped by the syn- 
thethic peptides are shown as stretches on the top of the 
plot. Also shown is the helical wheel representation of 
some of the peptides to demonstrate their amphipathic 
structure (Fig. 2). It can be seen that the hydrophobic 
residues are located on one side and the hydrophilic 
residues on the opposite side of the wheel. 
The second technique of T-epitope prediction pro- 
posed by Rothbard and Taylor [14] is based on sequence 
pattern recognition. The proposed pattern is composed 
of a charged residue or a glycine followed by two or three 
hydrophobic residues and the polar or charged residue 
at the C-terminus, and fits well to the amphipathic helix 
model, In contrast to the first technique the latter is 
based on a typical ‘all-or-none’ principle. Searching for 
T-cell epitopes using Rothbard’s characteristic frag- 
ments usually leads to an over-prediction of probable 
epitopes. The second disadvantage of this method is that 
an estimation of the preference of any site (i.e. ranging 
of sites) is impossible. We used this method together with 
the amphipathic helices searching program in order to 
select sites both amphipathic and containing the charac- 
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Fig. 1. Amphipatbicity profile of HAV VP1 capsid protein. Dashes on 
the top correspond to the regions overlapped by synthetic peptides. 
teristic pattern. We included the standard Gamier-Rob- 
son method [15] in our program set for estimation of 
conformational preference of sites in question. Frag- 
ments with high turn and/or coil preferences were 
excluded from further analysis because our previous in- 
vestigations had indicated the low probability of these 
conformations for T-epitopes. 
Once calculations had been performed the following 
segments of HAV capsid proteins were selected for syn- 
thesis: 75-92, 115-139 and 209-221 of VPl, 69-99 and 
80-99 of VP2, 45-57 and 137-150 of VP3 and l-23 of 
VP4 (Table 1). 
In addition we used peptides synthesised earlier as 
probable B-epitopes [5] that would be T-epitopes accord- 
ing to calculations (10-33 and 276-298 of VPl) or were 
overlapping with them (1-17, 1 l-25 and 75-85 of VPl). 
To determine whether a peptide could be considered 
a T-epitope, mice were primed with the free peptide and 
then proliferation of lymph node T-cells was estimated 
by measuring the incorporation of [3H]thymidine. Each 
peptide was also tested for its mitogenic activity. For this 
purpose, serial peptide dilutions were added to a suspen- 
sion of lymphocytes from lymph nodes of mice that had 
not been primed with peptide but were immunised with 
an emulsion containing PBS and CFA. In this case, there 
was no increase in thymidine incorporation by cell cul- 
tures after applying the tested peptide (data not shown). 
Of fifteen tested peptides, nine induced proliferation of 
primed lymphocytes with a SI from 2 to 6 (Table 2). As 
a rule, stimulation of lymphocyte proliferation depended 
upon mouse haplotype. This fact is observed for all the 
peptides with the exeption of peptides 10-33 and 276 
298 of VP1 protein, that stimulated lymphocyte prolifer- 
ation of all the mouse strains used. The shortened ana- 
logue of VPl-(lO-33), peptide VPl-(11-25) did not 
induce proliferation of CBA mice lymphocytes, whereas 
peptide VPl-(1-17) did not influence proliferation of 
lymphocytes from any of the tested strains of mice. On 
Table 1 
Synthetic peptides from the HAV capsid proteins 
Protein Segment Amino acid sequence 
VP1 1-17 VGDDSGGFSTTVSTEQN 
10-33 TTVSTEQNVPDPQVGITTMRDLKG 
1 l-25 TVSTEQNVPDPQVGI 
75-85 GESRHTSDHMS 
75-92 GESRHTSDHMSIYKFMGR 
107-126 YTFPITLSSTSNPPHGLPST 
115-126 STSNPPHGLPST 
115139 STSNPPHGLPSTLRWFFNLFQLYRG 
209-221 YAVSGALDGLGDK 
276298 MSRIAAGDLESSVDDPRSEEDRR 
VP2 69-99 LTTHALFHEVAKLDWKLLYNEQFAVQGLLR 
SO-99 KLDVVKLLYNEQFAVQGLLR 
VP3 45-57 GIKITHFTTWTSI 
137-150 PGNELIDVTGITLK 
VP4 l-23 MNMSKQGIFQTVGSGLDHILSLA 
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Fig. 2. Helical wheel presentation of peptides VPl-(115-139) (A) and VPl-(209-221) (B). Amino acid side chains are projected onto a plane 
perpendicular to the axis of the a-helix. Adjacent side chains in the sequence are separated by 100” of an arc on the wheel. Hydrophobic residues 
are circled. 
the basis of the results obtained, we can assume localisa- 
tion of the immunoactive site in region 17-33 of VP1 
protein inducing lymphocyte proliferation independent 
of testing strains of mice. There are possible T-epitopes 
in this region and in the region 276298 of VP1 protein 
recognising distinct molecules of Ia proteins, as was de- 
termined for the malaria T-cell epitopes [16]. 
Peptide VPl-(1 M-139) induced a proliferative re- 
sponse in F,(BALB/c x C,,Bl,) and F,(CBA x C,,Bl,) 
mice (data not shown). Its analogues VPl-(107-126) and 
VPl-(115-126), did not induce a proliferative response 
in any of the strains of mice primed with these peptides, 
however, both peptides initiated an increase in SI up to 
4 and 5, respectively, in Fi(CBA x C,,Bl,) mice primed 
with VPl-( 115-139) peptide (data not shown). A similar 
Table 2 
Ability of peptides from the HAV capsid proteins to induce a T-cell 
proliferative response in mice primed with these peptides 
Peptide Stimulation index* 
BALB/c F,BALB/c x C,,Bl& CBA 
VPl-(1-17) 1.2 1.2** 1.2 
VPl-(10-33) 4.2 6.0 2.1 
VPl-(11-25) 2.1 2.5** 1.3 
VPl-(75-92) 6.2 2.2 1.1 
VPl-(75-85) 1.1 1.0 1.0 
VPl-(115139) 1.0 2.0 1.1 
VPl-(107-126) 1.1 1.0 ND 
VPl-(115-126) 1.0 0.9 ND 
VPl-(209-221) 1.1 2.2 1.0 
VPl-(276-298) 2.5 4.0 2.1 
VP2-(69-99) 2.4 2.1 1.0 
VP2-(S&99) ND 1.2 1.2 
VP3-(45-57) 1.2 6.1 2.0 
VP3-(137-150) 1.5 1.7 1.8 
VP4-(1-23) 1.1 2.2 1.5 
Con A 9.1 10.2 8.1 
ND, no data; Con A, concanavalin A. 
*The highest SI value, obtained with optimal peptide concentrations 
(100-250 &ml), is presented. 
**Results obtained with F,(CBA x C5rB16) mice. 
effect was not detected with lymphocytes from CBA and 
BALB/c mice. 
In conclusion, we have demonstrated that almost all 
the predicted T-epitopes influenced the proliferation of 
lymphocytes in mice primed with the peptides and this 
influence depended on the strain of mouse. As an excep- 
tion to this rule we found immunodominant promiscu- 
ous sites in the regions 17-33 and 276-298 of VP1 capsid 
protein activating lymphocytes of all mouse haplotypes. 
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